Ind-Swift Laboratories shifts focus to formulations, divests API business

Ind-Swift Laboratories Limited announced the successful completion of a two-year merger process, unifying the company and divesting its API business to Synthimed Labs Pvt Ltd for C1,650 crore. This strategic pivot marks a new beginning, with the company now debt-free and solely focused on formulations. The annual report for fiscal year 2024–25, covering the period up to March 31, 2025, highlights this transformation, showing a total revenue of C63,092.16 lakhs (standalone) and C64,309.49 lakhs (consolidated) for FY25.

The company's performance in FY25 reflects a deliberate focus on debt retirement and the merger. Export revenues contributed C39,923.33 lakhs, driven by the Punjab 100% EOU unit catering to regulated and semi-regulated markets, along with growing CDMO contracts. The domestic formulations business contributed C15,041.34 lakhs, with notable traction in gynaecology and paediatrics. Innovation remains a core pillar, with 30+ products in the pipeline and 15+ developed in FY24–25.

The annual general meeting will be held on Monday, September 29, 2025, at 11:30 A.M. via video conference. Key resolutions include the ratification of remuneration for cost auditors and the appointment of secretarial auditors and independent directors. The company also disclosed preferential allotment of 2,60,00,000 fully convertible warrants, raising C314.60 crore, to strengthen its financial flexibility and support growth initiatives.